Aim Immunotech INC. (AIM) — SEC Filings

Q: What are the key financial highlights for Aim Immunotech INC.?

Key financial highlights for Aim Immunotech INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Aim Immunotech INC.?

Key executives at Aim Immunotech INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Aim Immunotech INC. stock?

Risk factors for Aim Immunotech INC. (AIM) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Aim Immunotech INC.?

Forward-looking statements and predictions from Aim Immunotech INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Aim Immunotech INC.. Recent 8-K filing on Dec 17, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Aim Immunotech INC. on SEC EDGAR

Overview

Aim Immunotech INC. (AIM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 17, 2025: AIM ImmunoTech Inc. filed an 8-K on December 17, 2025, reporting on matters submitted to a vote of security holders as of December 16, 2025. The filing does not contain specific details about the vote or the matters discussed.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 5 bearish, 43 neutral, 2 mixed. The dominant filing sentiment for Aim Immunotech INC. is neutral.

Filing Type Overview

Aim Immunotech INC. (AIM) has filed 21 8-K, 3 S-1, 4 10-Q, 3 S-1/A, 1 DEF 14A, 1 10-K, 13 DEFA14A, 3 SC 13D/A, 1 SC 13G with the SEC between Sep 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

AIM ImmunoTech Files 8-K on Shareholder Vote Matters — 8-K · Dec 17, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K on December 17, 2025, reporting on matters submitted to a vote of security holders as of December 16, 2025. The filing does not
AIM ImmunoTech Launches Rights Offering Amidst Promising Cancer, Antiviral Trials — S-1 · Dec 12, 2025 Risk: high
AIM ImmunoTech Inc. (AIM) is conducting a Rights Offering to purchase up to 12,000 Units, each consisting of one share of Series G Convertible Preferred Stock a
AIM ImmunoTech Enters Material Definitive Agreement — 8-K · Nov 19, 2025 Risk: medium
On November 18, 2025, AIM ImmunoTech Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as H
AIM ImmunoTech Narrows Losses Amid Revenue Dip, Delisting Scare — 10-Q · Nov 17, 2025 Risk: high
AIM ImmunoTech Inc. reported a net loss of $3.284 million for the three months ended September 30, 2025, a decrease from the $3.700 million net loss in the same
AIM ImmunoTech Files 8-K for Material Agreement — 8-K · Oct 29, 2025 Risk: medium
AIM ImmunoTech Inc. filed an 8-K on October 29, 2025, reporting an entry into a material definitive agreement and filing financial statements and exhibits. The
AIM ImmunoTech Files 8-K with Financials — 8-K · Oct 20, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K on October 20, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as
AIM ImmunoTech's Financial Woes Deepen Amid Delisting, Cash Burn — 10-Q · Aug 14, 2025 Risk: high
AIM ImmunoTech Inc. reported a significant increase in net loss for the six months ended June 30, 2025, reaching $6.499 million, compared to $7.653 million for
AIM ImmunoTech Files 8-K for Material Agreement — 8-K · Jul 31, 2025 Risk: medium
AIM ImmunoTech Inc. filed an 8-K on July 30, 2025, reporting the entry into a material definitive agreement. The filing also includes other events and financial
AIM ImmunoTech Files 8-K — 8-K · Jul 28, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K on July 28, 2025, reporting other events and financial statements. The company, formerly known as Hemispherx Biopharma Inc., is
AIM ImmunoTech Amends S-1 for Continuous Offering — S-1/A · Jul 22, 2025 Risk: medium
AIM ImmunoTech Inc. filed an S-1/A on July 22, 2025, for a delayed or continuous offering of securities under Rule 415, indicating a strategic move to secure fu
AIM ImmunoTech Files S-1/A for Flexible Capital Raise — S-1/A · Jul 15, 2025 Risk: medium
AIM ImmunoTech Inc. filed an S-1/A on July 15, 2025, for a delayed or continuous offering of securities under Rule 415, indicating a strategic move to secure fu
AIM ImmunoTech Faces Delisting Concerns — 8-K · Jun 20, 2025 Risk: high
AIM ImmunoTech Inc. filed an 8-K on June 20, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule on June 17, 2025. The filing a
AIM ImmunoTech Inc. Files 8-K Amid Listing Concerns — 8-K · Jun 12, 2025 Risk: high
AIM ImmunoTech Inc. filed an 8-K on May 29, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company also filed amendme
AIM ImmunoTech Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
AIM ImmunoTech Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Hemispherx Biopharma Inc., is focused on biological products. Key
AIM ImmunoTech Files 8-K on Shareholder Votes and Financials — 8-K · May 1, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K on May 1, 2025, reporting on matters submitted to a vote of security holders and financial statements as of April 30, 2025. The
AIM ImmunoTech Faces Delisting Concerns — 8-K · Apr 7, 2025 Risk: high
AIM ImmunoTech Inc. filed an 8-K on April 7, 2025, reporting events as of April 4, 2025. The filing indicates a potential notice of delisting or failure to meet
AIM ImmunoTech Files 8-K for Material Agreement — 8-K · Apr 4, 2025 Risk: medium
AIM ImmunoTech Inc. filed an 8-K on April 4, 2025, reporting a material definitive agreement and financial statements. The filing pertains to the period ending
AIM ImmunoTech Files Definitive Proxy Statement — DEF 14A · Apr 2, 2025 Risk: medium
AIM ImmunoTech Inc. filed a definitive proxy statement (DEF 14A) on April 2, 2025, for its special meeting of stockholders. The filing details information relat
AIM ImmunoTech Files 2024 10-K — 10-K · Mar 27, 2025 Risk: medium
AIM ImmunoTech Inc. filed its 2024 10-K on March 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly Hemispherx Biopharma Inc
AIM ImmunoTech Files 8-K Current Report — 8-K · Feb 28, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K on February 28, 2025, reporting an event on February 26, 2025. The filing is a current report under Section 13 or 15(d) of the
AIM ImmunoTech Files 8-K on Officer/Director Changes & Financials — 8-K · Feb 26, 2025 Risk: medium
AIM ImmunoTech Inc. filed an 8-K on February 26, 2025, reporting on events as of February 24, 2025. The filing covers the departure of directors or certain offi
AIM ImmunoTech Files 8-K — 8-K · Feb 11, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K on February 11, 2025, reporting other events and financial statements. The company, formerly known as Hemispherx Biopharma Inc.
AIM ImmunoTech Files 8-K — 8-K · Feb 7, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K on February 7, 2025, reporting other events and financial statements. The company, formerly known as Hemispherx Biopharma Inc.,
AIM ImmunoTech Files 8-K — 8-K · Feb 5, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K report on February 5, 2025, to disclose other events and financial statements. The filing does not contain specific financial f
AIM ImmunoTech Files S-1/A Amendment — S-1/A · Feb 3, 2025 Risk: medium
AIM ImmunoTech Inc. filed an S-1/A amendment on February 3, 2025, detailing its financial structure. The filing includes information on Series A Junior Particip
AIM ImmunoTech Files S-1 for Public Offering — S-1 · Jan 23, 2025 Risk: medium
AIM ImmunoTech Inc. filed an S-1 form on January 23, 2025, indicating a public offering of its securities. The company, previously known as Hemispherx Biopharma
AIM ImmunoTech Appoints New Chief Medical Officer — 8-K · Dec 23, 2024 Risk: medium
AIM ImmunoTech Inc. announced on December 19, 2024, the appointment of Dr. Michael J. Harbut as Chief Medical Officer. Dr. Harbut brings extensive experience in
AIM ImmunoTech Files 8-K on Shareholder Vote Matters — 8-K · Dec 20, 2024 Risk: low
AIM ImmunoTech Inc. filed an 8-K on December 20, 2024, reporting on matters submitted to a vote of its security holders on December 17, 2024. The filing details
AIM ImmunoTech Distributes Stockholder Correspondence — DEFA14A · Dec 17, 2024 Risk: low
AIM ImmunoTech Inc. filed a DEFA14A on December 17, 2024, indicating they distributed correspondence to certain stockholders on December 16, 2024. This filing i
AIM ImmunoTech: Ownership Filing Amendment — SC 13D/A · Dec 17, 2024 Risk: medium
On December 17, 2024, Paul W. Sweeney, Ted D. Kellner, and Wayne Springate filed an amendment (No. 9) to their Schedule 13D for AIM ImmunoTech Inc. The filing i
AIM ImmunoTech Files Definitive Proxy Materials — DEFA14A · Dec 16, 2024 Risk: low
AIM ImmunoTech Inc. filed a DEFA14A on December 16, 2024, attaching a press release issued on the same date. This filing is a definitive additional material rel
AIM ImmunoTech Files Definitive Proxy Materials — DEFA14A · Dec 12, 2024 Risk: low
AIM ImmunoTech Inc. filed a DEFA14A on December 12, 2024, indicating it is providing definitive additional materials related to its proxy statement. The filing
AIM ImmunoTech Files Proxy Materials — DEFA14A · Dec 10, 2024 Risk: low
AIM ImmunoTech Inc. filed a DEFA14A on December 10, 2024, attaching a press release issued on the same date. This filing is a definitive additional material rel
AIM ImmunoTech Files Proxy Materials — DEFA14A · Dec 9, 2024 Risk: low
AIM ImmunoTech Inc. filed definitive additional materials on December 9, 2024, related to its proxy statement. The filing indicates no fee was required for this
AIM ImmunoTech Files Proxy Materials — DEFA14A · Dec 6, 2024 Risk: low
AIM ImmunoTech Inc. filed definitive additional materials on December 6, 2024, related to its proxy statement. The filing indicates no fee was required for this
AIM ImmunoTech Files Proxy Materials — DEFA14A · Dec 5, 2024 Risk: medium
AIM ImmunoTech Inc. filed a Definitive Additional Materials (DEFA14A) on December 5, 2024, related to its proxy statement. The filing includes a press release i
AIM ImmunoTech Files Proxy Materials — DEFA14A · Dec 4, 2024 Risk: low
AIM ImmunoTech Inc. filed definitive additional materials on December 4, 2024, related to its proxy statement. The filing indicates no fee was required for this
AIM ImmunoTech Files Proxy Materials — DEFA14A · Dec 2, 2024 Risk: low
AIM ImmunoTech Inc. filed a Definitive Additional Materials proxy statement on December 2, 2024, related to a press release issued on the same date. The filing
AIM ImmunoTech Files 8-K: Regulation FD, Other Events — 8-K · Nov 27, 2024 Risk: low
AIM ImmunoTech Inc. filed an 8-K on November 27, 2024, reporting on events that occurred on November 25, 2024. The filing includes information related to Regula
AIM ImmunoTech Files Proxy Materials — DEFA14A · Nov 25, 2024 Risk: low
AIM ImmunoTech Inc. filed a Definitive Additional Materials filing on November 25, 2024, related to its proxy statement. This filing includes a press release is
AIM ImmunoTech Files Proxy Statement — DEFA14A · Nov 22, 2024 Risk: low
AIM ImmunoTech Inc. filed a DEFA14A on November 22, 2024, indicating it presented an investor presentation to Institut. The filing is a definitive additional ma
AIM ImmunoTech Files S-1 for Public Offering — S-1 · Nov 15, 2024 Risk: medium
AIM ImmunoTech Inc. filed an S-1 registration statement with the SEC on November 15, 2024, to register securities for public sale. The company, formerly known a
AIM ImmunoTech Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
AIM ImmunoTech Inc. filed its Q3 10-Q report for the period ending September 30, 2024. The company, formerly known as Hemispherx Biopharma Inc., is involved in
SC 13G Filing — SC 13G · Nov 14, 2024
AIM ImmunoTech Files Definitive Proxy Materials — DEFA14A · Nov 8, 2024 Risk: low
AIM ImmunoTech Inc. filed a Definitive Additional Materials proxy statement on November 8, 2024. This filing relates to the company's proxy statement and is not
AIM ImmunoTech Files Proxy Statement — DEFA14A · Nov 4, 2024 Risk: low
AIM ImmunoTech Inc. filed a DEFA14A on November 4, 2024, attaching a press release. The filing is related to proxy materials and indicates no fee was required f
AIM ImmunoTech Files 8-K: Agreements, Equity Sales, and Financials — 8-K · Oct 1, 2024 Risk: medium
AIM ImmunoTech Inc. filed an 8-K on September 30, 2024, reporting on a material definitive agreement, unregistered sales of equity securities, and other events.
AIM ImmunoTech CFO Departs, New Director Appointed, $10M Stock Sale — 8-K · Sep 12, 2024 Risk: medium
AIM ImmunoTech Inc. announced on September 11, 2024, the departure of its Chief Financial Officer, Elizabeth L. McGovern, effective September 10, 2024. The comp
Sweeney & Kellner Amend AIM ImmunoTech Filing — SC 13D/A · Sep 11, 2024 Risk: medium
On September 11, 2024, Paul W. Sweeney and Ted D. Kellner, as part of the Paul W. Sweeney Group, filed an amendment (No. 8) to their Schedule 13D for AIM Immuno
AIM ImmunoTech: Ownership Update Filed — SC 13D/A · Sep 3, 2024 Risk: medium
On September 3, 2024, Todd Deutsch and Ted D. Kellner filed an amendment (No. 7) to their Schedule 13D for AIM ImmunoTech Inc. The filing indicates a change in

Risk Profile

Risk Assessment: Of AIM's 49 recent filings, 6 were flagged as high-risk, 21 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Aim Immunotech INC.'s most recent 10-Q filing (Nov 17, 2025):

Revenue: $26,000
Net Income: -$3,284,000
EPS: -$1.57
Debt-to-Equity: N/A
Cash Position: $2,347,000
Operating Margin: N/A
Total Assets: $5,494,000
Total Debt: $11,571,000

Key Executives

Thomas K. Equels
Ocala, Florida
Richard Feiner, Esq.
Barry I. Grossman, Esq.
Matthew Bernstein, Esq.
Dr. Michael J. Harbut
Paul W. Sweeney
Ted D. Kellner
Wayne Springate
Todd Deutsch
Elizabeth L. McGovern
Dr. Michael T. Har-Ding
John J. Harrington

Industry Context

The immuno-pharma sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like AIM focus on novel therapies for complex diseases such as cancer and viral infections, often targeting unmet medical needs. The competitive landscape includes large pharmaceutical companies with substantial resources and numerous smaller biotech firms vying for market share and investment.

Top Tags

proxy-statement (14) · corporate-governance (10) · sec-filing (10) · financials (9) · filing (8) · biotech (6) · Biotechnology (5) · material-agreement (4) · 8-K (4) · Oncology (3)

Key Numbers

Subscription Price per Unit: $1,000 — Price for one Unit in the Rights Offering
Maximum Units Offered: 12,000 — Total number of Units available for purchase in the Rights Offering
Dealer-Manager Cash Fee: 8.0% — Percentage of gross proceeds paid to Maxim Group LLC
Dealer-Manager Expense Reimbursement Cap: $125,000 — Maximum amount reimbursed to Maxim Group LLC for expenses
Common Stock Price: $1.55 — Last reported sale price of AIM common stock on December 1, 2025
Objective Response Rate (ORR): 50% — Achieved in the Phase 2 ovarian cancer trial with Ampligen, pembrolizumab, and cisplatin
Subjects Treated: 14 — Number of subjects treated in the DURIPANC Study as of July 2025
Subjects Enrolled: 80 — Number of subjects enrolled in the AMP-518 Phase 2 study for Post-COVID conditions
Complete Responses: 5 — Number of patients with complete response in the ovarian cancer trial
Partial Responses: 7 — Number of patients with partial response in the ovarian cancer trial
Total Revenues (Q3 2025): $26,000 — Decreased from $35,000 in Q3 2024
Total Revenues (YTD Q3 2025): $67,000 — Decreased from $125,000 in YTD Q3 2024
Net Loss (Q3 2025): $3.284 million — Improved from $3.700 million in Q3 2024
Net Loss (YTD Q3 2025): $9.783 million — Improved from $11.353 million in YTD Q3 2024
Research and Development (Q3 2025): $607,000 — Decreased from $1.437 million in Q3 2024

Related Companies

AZN · MRK · AIMI

Frequently Asked Questions

What are the latest SEC filings for Aim Immunotech INC. (AIM)?

Aim Immunotech INC. has 50 recent SEC filings from Sep 2024 to Dec 2025, including 21 8-K, 13 DEFA14A, 4 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of AIM filings?

Across 50 filings, the sentiment breakdown is: 5 bearish, 43 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Aim Immunotech INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Aim Immunotech INC. (AIM) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Aim Immunotech INC.?

Key financial highlights from Aim Immunotech INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for AIM?

The investment thesis for AIM includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Aim Immunotech INC.?

Key executives identified across Aim Immunotech INC.'s filings include Thomas K. Equels, Ocala, Florida, Richard Feiner, Esq., Barry I. Grossman, Esq., Matthew Bernstein, Esq. and 8 others.

What are the main risk factors for Aim Immunotech INC. stock?

Of AIM's 49 assessed filings, 6 were flagged high-risk, 21 medium-risk, and 22 low-risk.

What are recent predictions and forward guidance from Aim Immunotech INC.?

Forward guidance and predictions for Aim Immunotech INC. are extracted from SEC filings as they are enriched.